UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED
30TH SEPTEMBER, 2001
(Rupees in million)
Quater Ended
Half year Ended
Year Ended 31.03.2001
(Audited)
30.09.2001
30.09.2000
30.09.2001
30.09.2000
1. Net Sales
3370.4
2696.6
6349.3
5114.5
10475.1
2. Other Income
119.4
100.0
180.6
175.8
386.1
3. Total Expenditure
a) (Increase)/ decrease in Stock-in -trade
100.9
(191.1)
(46.6)
(177.6)
(375.8)
b) Consumption of Materials
1468.3
1336.5
3006.0
2490.4
5236.6
c) Staff Cost
149.2
121.4
303.4
237.6
499.0
d) Other Expenditure
934.9
796.2
1796.6
1441.9
2961.1
4. Interest
4.7
1.3
7.2
5.3
8.3
5. Depreciation
47.5
45.0
95.0
82.5
156.3
6. Profit (+) / Loss (-) before Tax (1+2-3-4-5)
784.3
687.3
1368.3
1210.2
2375.7
7. Provision for Taxation
*180.0
170.0
*320.0
305.5
585.0
8. Net Profit (+) / Loss (-)(6-7)
604.3
517.3
1048.3
905.2
1790.7
9. Paid-up Equity Share Capital
599.7
599.7
599.7
599.7
599.7
10. Reserves excluding Revaluation Reserves ( as per balance-sheet of previous accounting year)
-
-
-
-
6540.5
11. Earning per Share ** Not Annualised
**10.07
**8.63
**15.09
29.86
12. Aggregate of Non-Promoter Shareholding - Number of Shares- Percentage of Shareholding
36541209
60.93
36490209
60.85
36541209
60.93
36490209
60.85
36505209
60.87
Notes :
1. The above results were taken on record at the meeting of the Board of Directors held on 20th October, 2001.
2. *Provision for tax includes deferred taxation .
3. The Company is exclusively in the pharmaceutical business segment. The capital employed as on 30th September, 2001 was Rs.6317.6 million.
